HC Wainwright & Co. maintains Immunocore Holdings at Buy, lowers price target to $80 from $100

HC Wainwright & Co. kept its Buy rating on Immunocore Holdings but reduced its price target to $80 from $100, a 20% cut. This implies a 152.1% upside from the Nov 9 closing price of $31.73, according to the firm.

Original reporting
Published Nov 10, 2026, 11:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Immunocore Holdings at Buy, lowers price target to $80 from $100 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The downgrade suggests a near-term price correction but does not introduce new catalysts.

02

Market read

Analyst rating adjustment with modest impact; primarily relevant to existing shareholders.

03

What to watch

No new clinical data or corporate actions accompany the target change.

Relevance 5/10Novelty 5/10Timing: same-day release

Background

HC Wainwright lowered its price target for Immunocore Holdings, citing revised expectations.

Market effects

Minimal impact on biotech sector; price target change reflects analyst view only.

Limited to UK biotech investors.

Low

Counterpoint

The target cut may be overly cautious; upside potential remains if pipeline advances.

Key entities

  • HC Wainwright & Co.

    Equity research firm providing the rating and target.

Related articles

$IMCRMed

Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary

Immunocore reported a 1.4% YoY revenue decline to $102.22M in Q3 2026, with a widened net loss of $14.22M. U.S. sales fell due to stocking adjustments and fewer sales weeks, partially offset by European and international growth. R&D spending increased, impacting results. KIMMTRAK is approved in 39 countries, and TEBE-AM Phase 3 trial enrollment is complete, with data expected in Q2 2027.